Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

Juanita S. Lopez, Seock-Ah Im, Sophie Postel-Vinay, Mario Campone, Anthony B. El-Khoueiry, Wassim Abida, Tobias Arkenau, Keun-Wook Lee, Sun Young Rha, Duncan I. Jodrell, Rebecca Roylance, Itziar Irurzun-Arana, Gemma N. Jones, Natalia Lukashchuk, Christine Stephens, Conor Norris, Arsène-Bienvenu Loembé, Emma Dean, Matthew G. Krebs

Open source

DOI: 10.1038/s41416-026-03601-z
Published: 2026-09-30
Container: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-026-03601-z,
  title = {Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer},
  author = {Juanita S. Lopez and Seock-Ah Im and Sophie Postel-Vinay and Mario Campone and Anthony B. El-Khoueiry and Wassim Abida and Tobias Arkenau and Keun-Wook Lee and Sun Young Rha and Duncan I. Jodrell and Rebecca Roylance and Itziar Irurzun-Arana and Gemma N. Jones and Natalia Lukashchuk and Christine Stephens and Conor Norris and Arsène-Bienvenu Loembé and Emma Dean and Matthew G. Krebs},
  year = {2026},
  journal = {British Journal of Cancer},
  doi = {10.1038/s41416-026-03601-z},
  url = {https://doi.org/10.1038/s41416-026-03601-z}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer
AU  - Juanita S. Lopez
AU  - Seock-Ah Im
AU  - Sophie Postel-Vinay
AU  - Mario Campone
AU  - Anthony B. El-Khoueiry
AU  - Wassim Abida
AU  - Tobias Arkenau
AU  - Keun-Wook Lee
AU  - Sun Young Rha
AU  - Duncan I. Jodrell
AU  - Rebecca Roylance
AU  - Itziar Irurzun-Arana
AU  - Gemma N. Jones
AU  - Natalia Lukashchuk
AU  - Christine Stephens
AU  - Conor Norris
AU  - Arsène-Bienvenu Loembé
AU  - Emma Dean
AU  - Matthew G. Krebs
PY  - 2026
JO  - British Journal of Cancer
DO  - 10.1038/s41416-026-03601-z
UR  - https://doi.org/10.1038/s41416-026-03601-z
ER  -

APA

Lopez, J. S., Im, S., Postel-Vinay, S., Campone, M., El-Khoueiry, A. B., Abida, W., Arkenau, T., Lee, K., Rha, S. Y., Jodrell, D. I., Roylance, R., Irurzun-Arana, I., Jones, G. N., Lukashchuk, N., Stephens, C., Norris, C., Loembé, A., Dean, E., & Krebs, M. G. (2026). Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03601-z

Source records

crossref · retrieved 2026-11-10T18:05:44.861Z